Short answer
Vaxcyte, Inc. (PCVX) filed an 8-K current report with the SEC on October 9, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation), Item 8.01 (Other Events). $575M raised through 1.50% convertible senior notes due October 2032, strengthening funding capacity at low cash interest cost.
Vaxcyte, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $575M raised through 1.50% convertible senior notes due October 2032, strengthening funding capacity at low cash interest cost
- Semiannual interest payments begin April 15, 2027, creating a long-dated fixed financing obligation
- Initial conversion price approximately $89.60 per share, potentially diluting shareholders if Vaxcyte’s stock appreciates
- Redemption permitted from October 22, 2029 if shares exceed 130% of the conversion price across specified trading periods
- Fundamental-change and delisting provisions give noteholders repayment rights, potentially increasing transaction-related financing constraints
Item 2.03 · Creation of a Direct Financial Obligation
- Item 2.03 points investors to Item 1.01 for details of any direct financial obligation
- Financial impact depends on the referenced agreement’s payment terms, commitments and timing
Item 8.01 · Other Events
- Concurrent offerings closed October 9, 2026, raising approximately $1.103 billion net for Vaxcyte
- Equity financing included 8,584,375 shares after full option exercise, creating substantial shareholder dilution
- Equity proceeds approximately $544.3 million, with shares priced at $64.00
- Convertible debt proceeds approximately $558.7 million, including $575.0 million principal at 1.50% due 2032
- Pre-funded warrants for 400,000 shares carry a $0.001 exercise price, adding potential future dilution
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Vaxcyte, Inc. 8-K filings
Get the next PCVX 8-K as it lands
Follow PCVX for push alerts, or ask the research agent what this filing means.